

### List of References Cited by Applicant

<b>Atty Docket No.:</b>	13783-105022		
<b>Applicant (s):</b>	Koenig et al.	<b>Serial No.:</b>	10/643,857
<b>Filing Date:</b>	August 14, 2003	<b>Group Art Unit:</b>	1644

#### U.S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass	Filing Date if appropriate
/CC/	A18	6,737,056	5/18/2004	Presta			
	A19	2004/0002587	1/1/2004	Watkins et al.			
	A20	2004/0185045 A1	9/23/2004	Koenig et al.			
	A21	2005/0037000 A1	2/17/2005	Stavenhagen et al.			
	A22	2005/0215767	9/29/2005	Koenig et al.			
	A23	2005/0260213 A1	11/24/2005	Koenig et al.			
	A24	2006/0013810	1/19/2006	Johnson et al.			
	A25	2006/0073142	4/6/2006	Chan et al.			
	A26	2006/0177439	8/10/2006	Koenig et al.			
	A27	2007/0253948	11/1/2007	Chan et al.			
	A28	11/754,015		Johnson et al.			5/25/2007
/CC/	A29	11/768,852		Johnson et al.			6/26/2007

#### FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation Yes/No
/CC/	B10	WO 99/19362	04/22/1999	PCT			
	B11	WO 99/41285	08/19/1999	PCT			
	B12	EP 0 332 865	09/20/1989	EP			
	B13	EP 0 629 703	12/21/1994	EP			
	B14	EP 0 953 639	11/03/1999	EP			
	B15	WO 04/016750 A2	2/26/2004	PCT			
	B16	WO 05/110474 A2	11/24/2005	PCT			
/CC/	B17	WO 05/115452 A2	12/08/2005	PCT			

/CC/	B18	WO 06/066078 A2	6/22/2006	PCT			
/CC/	B19	PCT/US07/72151		PCT; filing date: June 26, 2007			
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
/CC/	C79	Bewarder et al., In vivo and in vitro specificity of protein tyrosine kinases for immunoglobulin G receptor (FcγRII) phosphorylation, Mol Cell Biol. 1996; 16(9):4735-43.					
	C80	Boruchov et al., Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. The Journal of Clinical Investigation 115; 10:2914-2923.					
	C81	Fleit et al., Cross-linking of mAb to FcγRIIB results in tyrosine phosphorylation of multiple polypeptides including FcγRIIB itself. Leukocyte Typing V: White cell differentiation antigens (Schlossman, Boumsell, Glik, Harlan, Kishimoto, eds.) 1995; 826-827.					
	C82	Gamberale et al. To the editor: Expression of Fcγ receptors type II (FcγRII) in chronic lymphocytic leukemia B cells, Blood (Correspondence). 2003; 102(7):2698-2699.					
	C83	Kurlander et al. Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice. J Clin Invest. 1986; 77(6):2010-18.					
	C84	Looney et al. Human Monocytes and U937 cells bear two distinct Fc receptors for IgG. J Immunol. 1986; 136(5):1641-47.					
	C85	Maresco et al. The SH2-Containing 5'-inositol phosphate (SHIP) is tyrosine phosphorylated after Fcγ receptor clustering in monocytes. J Immunol. 1999; 162:6458-65.					
	C86	Ott et al. FcγRIIB as a potential molecular target for intravenous gamma globulin therapy. J Allergy Clin Immunol. 2001; 108:S95-S98.					
	C87	Pardridge et al., Blood-brain barrier drug targeting: The future of brain drug development. Molecular Interventions. 2003, 3;2:90-105. See particularly pages 91-96.					
	C88	Pulford et al. The immunocytochemical distribution of CD16, CD32, and CD64 antigens. Leukocyte Typing V: White Cell Differentiation antigens (Schlossman, Boumsell, Glik, Harlan, Kishimoto, eds.). 1995;817-821.					
	C89	Reff et al. A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications. Crit Rev Oncol Hematol. 2001; 40(1):25-35					
	C90	Schuna et al. New Drugs for the treatment of rheumatoid arthritis. Am J Health Syst Phar. 2000; 57:225-37.					
	C91	Su et al., Expression profile of FcγRIIB on leukocytes and its dysregulation in systemic lupus erythematosus. J. Immunol. 178:3272-3280, 2007					
	C92	Van de Winkel et al. CD32 cluster workshop report. Leukocyte Typing V: White Cell Differentiation Antigens (Schlossman, Boumsell, Glik, Harlan, Kishimoto, eds.). 1995;823-25.					
	C93	Vely et al. A new set of monoclonal antibodies against human Fc gamma RII (CD32) and Fc gamma RIII (CD16): characterization and use in various assays. Hybridoma. 1997; 16(6):519-28.					
/CC/	C94	Zola et al. CD32 (FcγRII). J Biol Regul Homeost Agents. 2000; 14(4):311-16.					

<b>EXAMINER</b>	/Chun Crowder/ (11/19/2007)	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

## List of References Cited by Applicant

<b>Atty Docket No.:</b>	12062-105022		
<b>Applicant (s):</b>	Koenig et al.	<b>Serial No.:</b>	10/643,857
<b>Filing Date:</b>	August 14, 2003	<b>Group Art Unit:</b>	1644

### U.S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass	Filing Date if appropriate

### FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation Yes/No

### OTHER REFERENCES (including Author, Title, Date, Pertinent Pages, Etc.)

/CC/	C78	Boruchov et al., Expression and Modulation of the Inhibitory Fcγ Receptor (CD32b) on Human Dendritic Cells (DCs). presented at , American Society of Hematology 45 <sup>th</sup> Annual Meeting and Exposition, December 7, 2003

EXAMINER /Chun Crowder/ (11/14/2007)

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.